INTRODUCTION
============

Human papillomaviruses (HPVs) are species-specific, epitheliotropic DNA viruses with over 120 types completely characterized today ([@bib2]). Infections are widespread and induce lesions from benign papilloma to intraepithelial neoplasia to carcinoma, the latter representing 5% ([@bib27]) of the global cancer burden. Persistent infection with a subset of mucosal HPVs causes high-grade intraepithelial neoplasias that eventually progress to invasive cancer of the cervix (CxCa) and of other anogenital and oropharyngeal sites. More than 15 high-risk (HR) types are found in almost all CxCas, causing 250,000 deaths in women worldwide every year ([@bib24]; [@bib7]). Low-risk (LR) mucosal HPVs cause anogenital warts in 30 million patients. Common cutaneous HPVs induce skin warts with substantial impact on high-prevalence groups such as children or immunocompromised individuals ([@bib40]; [@bib21]). Moreover, a distinct group of cutaneous (genus β) types have been implicated as subsidiary causative factor of nonmelanoma skin cancers, although this remains controversial for those other than patients with the rare genodermatosis Epidermodysplasia verruciformis ([@bib15]; [@bib3]). Recombinantly expressed major capsid protein L1 of papillomaviruses self-assembles into virus-like particles (L1-VLPs) ([@bib18], [@bib19]; [@bib10]; [@bib31]; [@bib37]) that have been introduced as prophylactic vaccines. Both (bivalent Cervarix and quadrivalent Gardasil) licensed vaccines comprise VLPs of HR HPV16/18, which cause 70% of cervical disease. One (quadrivalent) vaccine additionally contains VLPs of LR HPV6/11, causing 90% of genital warts. Prophylactic vaccination confers enduring yet predominantly vaccine type--restricted protection mediated by high-titer neutralizing antibodies. To target HPVs responsible for the remaining third of CxCas ([@bib24]), a nonavalent vaccine including 7 HR types is in clinical trials (<http://clinicaltrials.gov>). However, the complexity of such a vaccine is unlikely to reduce the already very high costs of current HPV vaccines, which may impede delivery to the developing world with the highest CxCa burden. Furthermore, a vaccination strategy against the many types causing skin papillomas (warts) has not been established ([@bib11]; [@bib34]). Papillomavirus minor capsid protein L2--based immunogens represent an alternative strategy to multivalent L1-VLP vaccines. The amino (N) terminus of L2 contains highly conserved motifs that are buried in native virions and become exposed only shortly during the infectious process. However, immunization with L2 peptides alone can induce low-titer antibodies, which mediate cross-neutralization ([@bib6]; [@bib17]; [@bib30]; [@bib28]) *in vitro* and cross-protection in animal models *in vivo* ([@bib5]; [@bib8]). An HPV16 L2 peptide comprising amino acids (aa) 17--36 is a broadly cross-neutralization B-cell epitope recognized by mAb RG1 ([@bib9]). Owing to its essential role for viral infectivity and its high conservation within many types, the RG1 epitope may represent an attractive target to develop a broad-spectrum HPV vaccine. We have previously introduced chimeric RG1-VLP as a possible strategy to improve immunogenicity of the RG1 epitope by its genetic insertion into the immunogenic DE-surface loop of HPV16 L1 ([@bib35]; [@bib20]; [@bib33]; [@bib4]). Upon expression as a recombinant fusion protein, assembly into capsids repetitively displaying RG1 epitopes on the capsid surface (RG1-VLP) is highly efficient. Vaccination induced high-titer neutralizing antibodies against HPV16 and improved L2-specific antibodies. Then, available limited *in vitro* assays demonstrated cross-neutralization of mucosal HR HPV18/31/45/52/58, LR HPV HPV6/11, and a single genus β-type (HPV5) ([@bib33]). This study comprehensively examines RG1-VLP vaccine efficacy to cross-protect against all relevant mucosal HR HPVs *in vivo* and *in vitro*, endurance of protection (an important issue for L2-based vaccine development), and induction of cell-mediated immunity. Vaccine efficacy against natural infection was validated using authentic virion-based neutralization assays.

RESULTS
=======

We have shown previously that vaccination of rabbits and mice with recombinant RG1-VLP plus alum-MPL (aluminum hydroxide plus 3-O-desacyl-4′-monophosphoryl lipid A) adjuvant ([@bib33]) elicited high-titer neutralizing antibodies to HPV16 and cross-neutralizing antibodies to pseudovirion (PsV) of the limited number of then available mucosal HR HPV18/31/45/52/58, LR HPV6/11, and cutaneous β HPV5.

RG1-VLP vaccination induces a robust antibody response against the L2 epitope
-----------------------------------------------------------------------------

To assess the robustness of the humoral immune responses to RG1-VLP, eight additional rabbits were vaccinated either 4 or 3 times (New Zealand White (NZW) nos. 1--6: 4 × 50 μg and nos. 7--10: 3 × 20 μg) and sera drawn 2 weeks after the last boost. Robust antibody responses to L2 (titers of 2,500--12,500) were detected for both vaccination protocols using the 16L2 N-terminal peptide (aa 11--200) as ELISA antigen ([Supplementary Material](#sup1){ref-type="supplementary-material"} online). Conversely, reactivity was absent for rabbit antiserum to HPV16 wild-type L1-VLP as expected.

Antisera to RG1-VLP neutralize distantly related mucosal HPV types *in vitro*
-----------------------------------------------------------------------------

The spectrum of cross-neutralization induced by RG1-VLP vaccination was further explored by analyzing rabbit antisera (*n*=10) in neutralization assays for a large panel of genus-α HPV using additional PsV types ([Table 1](#tbl1){ref-type="table"}). Similar to findings reported previously for rabbits 1/2 (\*), the additional eight rabbits\' immune sera contained high-titer neutralizing antibodies against HPV16 (titers of 10,000--100,000). Broad-spectrum cross-neutralization was found for species α9 HPV31, 52, 58, 33, 35 (in 2, 5, 9, 6, and 9 out of 10 sera), α7 HPV18, 45, 39, 59, 68, 70 (9, 6, 5, 1, 2, 7/10), α5 HPV51, 26, 69 (3, 10, 2/10), α11 HPV73 and 34 (10 and 8/10) (titers from 25 to 10,000), but not for α6 HPV 56, 53, and 66. Cross-neutralization beyond mucosal HR types was analyzed for the most potent sera nos. 1/2 ([Table 2](#tbl2){ref-type="table"}). Apart from LR HPV6/11, α1 HPV32 (causing Heck\'s disease) was neutralized (titers of 50/100), whereas HPV44 (α10) sporadically found in genital warts was not neutralized. To narrow the gap between PsV-based *in vitro* assays and natural HPV infection, RG1-VLP-induced neutralizing antibodies were also detected using infectious native virions ([@bib12]). As shown in [Figure 1a](#fig1){ref-type="fig"}, HaCaT cells infected with HPV26 virions (lane 2) revealed a specific band corresponding to spliced viral mRNA in nested reverse transcriptase--PCR, in contrast to uninfected control cells (lane 1). Preincubation of virions with RG1-VLP antiserum (1:400) completely abolished mRNA detection, indicating viral neutralization (lane 4), whereas preimmune serum (lane 3), mAb RG1 ([@bib9]) (lane 5), or serum from a Gardasil-vaccinated individual (lane 6) had no effect. RG1-VLP antiserum also cross-neutralized LR HPV40 ([Figure 1b](#fig1){ref-type="fig"}; lanes 5 and 6) and HPV6 virions (see [Supplementary Material](#sup1){ref-type="supplementary-material"} online) at dilutions of 1:100--400. Taken together, the *in vitro* cross-neutralization spectrum of RG1-VLP vaccination includes almost all HR HPVs causing CxCas, as well as LR mucosal types in PsV and native virion--based assays.

Antisera to RG1-VLP cross-neutralize prevalent common cutaneous and HR β HPVs
-----------------------------------------------------------------------------

In immunocompetent individuals with palmoplantar and plane warts, the most frequently detected types are genus α HPV2/27/57 ([@bib32]), γ HPV4, μ HPV1, and α HPV3/10. Genus β HPV5/8 have been first identified in patients suffering from Epidermodysplasia verruciformis, whereas a possible role of β papillomavirus in non-melanoma skin cancer pathogenesis is still controversial. Thus, rabbit antisera nos. 1/2 were screened for cross-neutralization against available cutaneous HPVs in pseudovirion-based neutralization assay (PBNA; [Table 2](#tbl2){ref-type="table"}), showing previously reported cross-neutralization of HPV5(\*), and additionally of HPV3 (α2) and HPV76 (β4) (titers of 1,000/100), but not of HPV4 (γ1) or HPV38 (β2). Furthermore, antisera nos. 1 and 2 cross-neutralized native virions of HPV2 with titers of 800 and 1,600 ([Figure 1c](#fig1){ref-type="fig"}, lanes 5 and 11), and HPV27 at dilution 1:400 ([Supplementary Material](#sup1){ref-type="supplementary-material"} online). Interestingly, antiserum to HPV2 L1-VLP neutralized HPV27, as did antiserum to HPV27 L1-VLP (1:400), indicating that closely related genotypes HPV2 and HPV27 (α4) may represent common serotypes (antisera to HPV2/27 L1-VLP were a kind gift from L Gissmann, DKFZ, Heidelberg, Germany). Neither HPV1 nor HPV4 virions ([Supplementary Material](#sup1){ref-type="supplementary-material"} online) were cross-neutralized by RG1-VLP antiserum. Sera of 7/8 prepubertal girls were neutralizing against highly prevalent cutaneous HPV1 ([Supplementary Material](#sup1){ref-type="supplementary-material"} online), indicating robust seroconversion after natural infection, whereas serum from a Gardasil-vaccinated individual did not cross-neutralize cutaneous HPV4. Moreover, the cross-neutralization spectrum of RG1-VLP vaccine even extends to bovine papillomavirus type 1 in PBNA ([Table 2](#tbl2){ref-type="table"}).

RG1-VLP vaccination induces cellular immune responses
-----------------------------------------------------

The enzyme-linked immunospot analysis of splenocytes from mice vaccinated with RG1-VLP or similarly HPV16 L1-VLP showed IFN-γ-producing cells when stimulated with a previously described HPV16 L1 cytotoxic T lymphocyte epitope ([Supplementary Material](#sup1){ref-type="supplementary-material"} online), indicating the induction of a strong cellular immune response ([@bib26]). In contrast, stimulation of cells with the RG1 peptide did not result in significant IFN-γ production.

RG1-VLP antisera efficiently protect mice against experimental vaginal challenge with mucosal HPV *in vivo*
-----------------------------------------------------------------------------------------------------------

Given the broad spectrum of HR HPVs cross-neutralized *in vitro*, vaccine efficacy *in vivo* was determined using an experimental mouse model (adapted from [@bib29]). As expected, passive transfer of RG1-VLP antiserum reduced vaginal infection in mice challenged with HPV16 PsV to background levels, similar to HPV16 L1 VLP antiserum ([Figure 2a](#fig2){ref-type="fig"}). Importantly, mice were also cross-protected from infection with phylogenetically divergent types HPV31/33/35/52/58 (α9), HPV18/45/39/59/68 (α7), HPV34/73 (α11), HPV53/56/66 (α6), and HPV26/51 (α5), and LR HPV6 (α10) and HPV43 (α8) ([Figure 2b and c](#fig2){ref-type="fig"}). Indicative, yet statistically unsignificant, results were obtained for LR HPV44 (α10). The level of cross-protection by RG1-VLP antiserum was indistinguishable from that induced by type-specific antisera to the homologous L1-VLP, respectively, except for HPV53/43/44, for which protection was recognizably lower. In contrast, HPV16 L1-VLP antiserum showed predominantly type-restricted protection against homologous HPV16, with significant cross-protection against very closely related HPV31/33/35 and to a smaller extent against more divergent HPV56/59/6. Detectable *in vitro* cross-neutralization titers (⩾25) were always accompanied by cross-protection *in vivo* ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). However, RG1-VLP antisera also conferred complete (HPV56) or at least partial cross-protection (HPV53/66) *in vivo* ([Figure 2a and b](#fig2){ref-type="fig"}), for which types cross-neutralization was not detected *in vitro*, suggesting low sensitivity of current assays. To further demonstrate vaccine efficacy irrespective of subtle cross-neutralization titers *in vitro*, antisera nos. 6/10 were selected for *in vivo* assays. Antisera nos. 6/10 demonstrated a narrow cross-neutralization spectrum *in vitro* for only 6/19 or 3/19 mucosal HR types ([Table 1](#tbl1){ref-type="table"}). Although neither of the two sera cross-neutralized HPV31/45 *in vitro*, both effectively cross-protected against infection with HPV31/45 *in vivo* ([Figure 2c](#fig2){ref-type="fig"}).

Induction of long-lasting B-cell memory and cross-protection
------------------------------------------------------------

To examine long-term B-cell memory after RG1-VLP vaccination, rabbits 1/2 were housed for a further 10 months after the fourth immunization and boosted at week 52 with 50 μg of RG1-VLP ([Supplementary Material](#sup1){ref-type="supplementary-material"} online). When compared with sera drawn at week 10, cross-neutralization titers had declined 1--2 logs (HPV18/31) or beneath the level of detection (HPV45/52/58/6/5) in week 52. A similar 2-log decline was observed for neutralizing antibodies against HPV16, which are predominantly induced by the L1 scaffold of RG1-VLP. Importantly, boosting with RG1-VLP raised antibody titers to former levels or beyond. To determine whether cross-protection *in vivo* is also long lasting, antiserum drawn at week 52 was analyzed for cross-protection against *in vivo* challenge with HPV58. Although neutralization of HPV58 was no longer detectable *in vitro* at week 52, cross-protection was still conferred *in vivo* ([Figure 2d](#fig2){ref-type="fig"}), yet to a slightly lesser extent as compared with sera drawn at week 10 ([Figure 2b](#fig2){ref-type="fig"}).

DISCUSSION
==========

The search for second-generation HPV vaccines is driven by the need to protect against the plurality of carcinogenic genital HPV by safe and affordable formulations. Because licensed vaccines do not target HR HPVs other than HPV16/18, causing 30% of CxCas, cytological screening programs cannot be superseded. This major limitation in particular affects developing countries, which bear \>85% of the global CxCa burden. Moreover, precancerous cervical neoplasia with a substantial disease prevalence and morbidity in younger women is even more strongly associated with types other than HPV16/18 ([@bib38]). To extend protection to the most common oncogenic HPVs, a nonavalent L1-VLP vaccine (comprising seven HR and two LR types) is in clinical trials. Although such a highly multivalent L1 vaccine is expected to significantly increase the breadth of coverage, L2-based vaccines are attractive as single-antigen formulations targeting even more mucosal and, additionally, nongenital types. The spectrum of L2-mediated cross-neutralization by chimeric RG1-VLP has been analyzed by a limited number of *in vitro* assays, whereas the vaccine\'s efficacy to confer protection in mammals against infection with a broad range of HPVs has not been substantiated so far. In a very extensive comparison of HPV16 L1 VLP versus RG1-VLP (plus alum-MPL adjuvant) provided herein, RG1-VLP vaccination (cross-)protects with high efficacy *in vivo* against infection with 18 divergent HR types out of 4 different species (α5/7/9/11), which cause more than 95% of CxCas worldwide, and also partially protects against the remaining four types tested ([@bib7]). Mice were protected from vaginal challenge with large doses of mucosal PsV despite considerable antiserum dilution (∼1:50) into the mouse circulation. Interestingly, undetectable cross-neutralization *in vitro* did not stringently imply incomplete protection *in vivo*. In line with the recently reported insufficient sensitivity of current *in vitro* assays to detect anti-L2 antibodies, *in vivo* testing has become the gold standard in detecting neutralizing HPV antibodies ([@bib22]) and documenting vaccine efficacy. The results imply that the actual immunogenicity is substantially greater than that reflected by the standard *in vitro* neutralization assay, and suggest that this vaccine should have a significant impact not only on reducing the risk of CxCa but also on the overall incidence of genital HPV infection, thus providing a major advantage to HPV-based screening programs when compared with the current vaccines. Complementary *in vitro* assays were used to more extensively characterize the spectrum of cross-neutralization by RG1-VLP vaccination, which was not predicted by L1-based classification of papillomaviruses, the site of infection, or host species. In PBNA, variable (cross)-neutralization by RG1-VLP antiserum was detected for 17 mucosal HR types, whereas cross-protection *in vivo* was intact for the serum with least potency *in vitro*. Although technically demanding and limited to those few types available from productive lesions, neutralization assays using native virions may reflect viral infection more authentically than PBNA ([@bib23]). Reassuringly, the RG1-VLP antisera neutralized lesion-derived virions as well. The RG1-VLP antisera also cross-neutralized LR types HPV6/11 (α10), HPV32 (α1), HPV40 (α8), and cutaneous HPV2/27 (α4), HPV3 (α1), and HPV76 (β3), but not HPV1 (μ), HPV4 (γ), and HPV38 (β). On comparing the RG1 motifs of all types cross-neutralized, sequence homology to HPV16 RG1 was at least 60% (see [Supplementary Material](#sup1){ref-type="supplementary-material"} online). Whether this lower threshold of homology necessary for inducing cross-neutralization holds out in more sensitive *in vivo* assays needs to be demonstrated. Therefore, RG1-VLP vaccination is expected to protect against a substantial proportion of benign papillomas, including both sexually transmitted genital and nongenital skin warts. The latter is not only of tremendous clinical importance for the growing group of immunocompromised patients (e.g., organ-transplant recipients, HIV patients), but may have expanded relevance if these types contribute to the genesis of nonmelanoma skin cancers. Because the incidence of common skin warts peaks in early childhood, this would provide a rationale for implementing the vaccine into existing childhood programs. Various approaches to enhance cross-neutralizing L2 antibodies have been presented over the past years, including conjugation of L2 peptides to a T-helper epitope and a Toll-like receptor 2 ligand ([@bib1]), concatenated multimeric L2 peptide vaccination ([@bib13]), or display on bacteriophage ([@bib39]), adeno-associated virus ([@bib25]), or HPV L1-VLP ([@bib41]; [@bib35]; [@bib20]; [@bib33]; [@bib4]). Favorably, RG1-VLP vaccination plus alum-MPL (as in Cervarix) not only elicits robust antibody responses against RG1 in ELISA but also retains high-level protection against the most important HPV16. Therefore, RG1-VLP vaccination should provide strong protection not just against CxCas but also against the even higher percentage of noncervical cancers attributable to HPV16. In contrast, in a comprehensive direct comparison, HPV16 L1-VLP vaccination protected against HPV16 and 31 and only to a lower extent against 35, 39, 56, and 6. Licensed vaccines provide long-term protection of at least 8.5 years, and the antibody levels required are still unknown. Importantly, sera drawn 12 months after RG1-VLP vaccination completely protected mice against vaginal challenge with HR HPV58 *in vivo*. RG1-VLP holds promise as next-generation vaccine with broad efficacy against the vast majority of relevant mucosal and additional cutaneous HPVs, provides a rationale for childhood vaccination, and adds economic advantage of a single antigen formulation compared with multivalent L1-VLP formulations. As post-licensure data confirm excellent safety profiles for HPV L1-VLP vaccines, we infer that RG1-VLP vaccination may prove similarly safe, offering the possibility to evaluate vaccine immunogenicity in early-phase human trials.

MATERIALS AND METHODS
=====================

Chimeric RG1-VLP
----------------

Chimeric HPV16 L1--HPV16 L2 ~(aa\ 17--36)~ VLP (RG1-VLP) have been generated ([@bib33]) by the insertion of HPV16 L2 peptide aa 17--36 (RG1) ([@bib9]) into the DE-surface loop of HPV16 L1 and expressed in insect cells ([@bib18]).

Immunization
------------

NZW rabbits were immunized with 50 μg of RG1-VLP subcutaneously (weeks 0, 4, 6, and 8, *n*=6; NZW nos. 1--6) or 20 μg of RG1-VLP (weeks 0, 3, and 6, *n*=4; NZW nos. 7--10) (Charles River, Kisslegg, Germany) adjuvanted with alum-MPL (10:1) (Sigma Aldrich, St Louis, MO). Sera were drawn at weeks 10 (nos. 1--6) or 8 (nos. 7--10). Long-term antibody responses were determined for NZW nos. 1/2 kept at 10 months. Sera were drawn before and 14 days after final boost (week 52) and were stored at −20 °C. For type-specific L1 antisera, a single rabbit each was immunized with 20 μg PsV of HPV6/26/34/35/39/43/44/51/52/53/56/58/59/66/68/69, or 70, respectively (weeks 0, 3, and 6), in complete/incomplete Freund\'s adjuvant.

Native virion--based neutralization assays (reverse transcriptase--PCR)
-----------------------------------------------------------------------

Native virions HPV2/27/1/4 were extracted from plantar warts; HPV6 from genital warts; HPV26 from a highly differentiated carcinoma ([@bib12]); and HPV40 virions were provided by Neil Christensen (Hershey, PA) ([@bib14]). After mechanical disruption of wart tissue by high-speed homogenizer (Fastprep-24, MP Biomedicals, Eschwege, Germany) and centrifugation (14,000 r.p.m./4 °C/5 minutes), supernatants containing virions were used for neutralization assays ([@bib36]; [@bib35]). In brief, 3 × 10^5^ HaCaT keratinocytes were infected with virions that were either untreated or preincubated with rabbit antisera and incubated overnight. Cellular RNA was reverse transcribed, and spliced viral E1\^E4 mRNA was identified by 30-cycle nested PCR (95 °C/1 minute, 60 °C/1 minute, and 72 °C/3 minutes; for primer pairs see [Supplementary Material](#sup1){ref-type="supplementary-material"} online).

Murine vaginal challenge
------------------------

The intravaginal PsV challenge model ([@bib29]) was performed with slight modification ([@bib16]). Female Balb/C mice (groups of 5 or 10) were pretreated with 3 mg of progesterone subcutaneously medroxyprogesterone (Depocou, Pfizer, Vienna, Austria), and on day 3 they were passively transferred with 20 μl rabbit antiserum: RG1-VLP (pre)immune serum (rabbits 1, 6, and 10), or sera to L1-VLP of HPV16/31/33/45/6, to L1/L2-VLP of HPV18 (J Schiller, NIH, Bethesda, MD), to L1-DNA of HPV59/73, or to L1/L2-PSV of HPV26/34/35/39/51/52/53/56/58/66/68/69/ or 70, respectively. After 24 hours, vaginal microtrauma was induced by cervical cytobrush, and mice were challenged with luciferase-encoding PsV in 3% carboxymethylcellulose. After 3 days, 20 μl of luciferin (Caliper, Waltham, MA; 7.5 mg ml^−1^) was applied into the vagina, and infection was analyzed by bioluminescence imaging (IVIS 50, Caliper). Data are given with background signal subtracted (mice challenged with carboxymethylcellulose).

Statistical methods
-------------------

Statistical analysis was performed using Microsoft Excel (heteroscedastic two-tailed unpaired *t*-test to evaluate *P*-values).

Standard techniques such as ELISA, PBNA, and enzyme-linked immunospot assays are described in [Supplementary Material](#sup1){ref-type="supplementary-material"} online.

Consent and approval
--------------------

Human sera and tissue samples were collected after written informed consent of the patient or the patient\'s guardian in accordance with the Ethics Committee of the Medical University Vienna (ECS 1327/2012). The study was conducted according to the Declaration of Helsinki Principles.

Animal welfare
--------------

Animal studies have been approved (BMWF-66.009/0173-1I/3b/2011) and animal care was in accordance with the guidelines of the Austrian Federal Ministry for Science and Research.
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![***In vitro* reverse transcriptase--PCR (RT--PCR) neutralization assays using native cutaneous and mucosal high-risk (HR) and low-risk (LR) human papillomavirus (HPV) virions.** HaCaT cells were incubated with native virions of (**a**) mucosal HR HPV26, (**b**) mucosal LR HPV40, and (**c**) cutaneous HPV2. Infection was detected by amplification of spliced viral mRNA. Cells were either mock treated (cells only) or infected with native virus (+) in the absence of serum (no serum), or with virions preincubated with (pre)immune sera at indicated dilutions. Neither mAb RG1 nor a human antiserum from a Gardasil-immunized individual neutralized infection with HPV26.](jid2013253f1){#fig1}

![**Cross-protection against vaginal challenge with mucosal high-risk (HR) and low-risk (LR) human papillomavirus (HPV) *in vivo*.** (**a**--**d**) *In vivo* vaginal challenge with mucosal HPV in mice, passively transferred with RG1-VLP antiserum. Female Balb/c mice were injected intraperitoneally (i.p.) with 20 μl of rabbit (A) preimmune serum; (B) RG1-VLP immune serum (serum no. 1) (**a**, **b**); serum no. 6, no. 10 (**c**); (C) HPV16 L1-VLP antiserum; or (D) L1 antiserum to the respective homologous type. Mice were challenged with pseudovirion (PsV) of (**a**) HPV16; (**b**) the next 11 most prevalent HR types HPV18, 45, 31, 33, 52, 58, 35, 39, 51, 59, and 68, and less frequent (\<1%) types in cervical cancer (CxCa) HPV56, 73, 26, 53, 66, 34; LR HPV6, 43, and 44; or (**c**) high-risk HPV31 and 45. (**d**) An RG1-VLP rabbit antiserum (no. 1) drawn at week 52 (10 months following the third boost with *in vitro* titer of \<25 to HPV58) was analyzed for cross-protection against challenge with HPV58 (B no. 1, week 52). Antisera to (**d**, C) HPV16 L1-VLP and (**d**, D) HPV58 L1/L2 PsV drawn 2 weeks after the third boost were used as controls. Luciferase activity in bioluminescence imaging (Y axis: average radiance; p/s/cm^2^/sr) is given with the respective background luminescence (unvaccinated mice challenged with carboxymethylcellulose (CMC) only) subtracted from all data points. *P*-values comparing groups A and B are indicated by \**P*⩽0.05, \*\**P*⩽0.01, and \*\*\**P*⩽0.005.](jid2013253f2){#fig2}

###### Cross-neutralization of mucosal HR HPV by RG1-VLP antisera in PBNA *in vitro*

          **Neutralizing titers against high-risk genital HPV pseudovirions**                                                                                 
  ------- --------------------------------------------------------------------- ------------ --------- --------- -------- -------- -------- -------- -------- --------
  HPV16   100,000 \*                                                            100,000 \*   100,000   100,000   10,000   10,000   10,000   10,000   10,000   10,000
  HPV18   1,000\*                                                               1,000 \*     100       100       1,000    100      100      100      100      \<25
  HPV45   1,000 \*                                                              100 \*       \<25      50        1,000    \<25     \<25     50       100      \<25
  HPV31   10,000 \*                                                             1,000 \*     \<25      \<25      \<25     \<25     \<25     \<25     \<25     \<25
  HPV52   100 \*                                                                50 \*        50        \<25      25       \<25     \<25     \<25     25       \<25
  HPV58   1,000 \*                                                              1,000 \*     100       100       100      25       50       100      1,000    \<25
  HPV33   100                                                                   100          50        25        100      \<25     \<25     \<25     100      \<25
  HPV35   1,000                                                                 1,000        100       100       1,000    100      50       100      1,000    \<25
  HPV39   500                                                                   100          \<25      25        100      \<25     \<25     \<25     50       \<25
  HPV56   \<25                                                                  \<25         \<25      \<25      \<25     \<25     \<25     \<25     \<25     \<25
  HPV59   25                                                                    \<25         \<25      \<25      \<25     \<25     \<25     \<25     \<25     \<25
  HPV68   1,000                                                                 100          \<25      \<25      \<25     \<25     \<25     \<25     \<25     \<25
  HPV73   1,000                                                                 1,000        1,000     100       100      100      50       25       100      25
  HPV51   25                                                                    \<25         \<25      \<25      \<25     \<25     \<25     50       \<25     50
  HPV26   100                                                                   100          100       100       100      50       25       1,000    100      100
  HPV53   \<25                                                                  \<25         \<25      \<25      \<25     \<25     \<25     \<25     \<25     \<25
  HPV69   \<25                                                                  \<25         \<25      \<25      100      \<25     \<25     \<25     50       \<25
  HPV66   \<25                                                                  \<25         \<25      \<25      \<25     \<25     \<25     \<25     \<25     \<25
  HPV70   100                                                                   50           \<25      100       1,000    50       \<25     50       100      \<25
  HPV34   1,000                                                                 1,000        100       100       1,000    50       \<25     \<25     100      25

Abbreviations: alum-MPL, aluminum hydroxide plus 3-O-desacyl-4′-monophosphoryl lipid A; HPV, human papillomavirus; HR, high risk; NZW, New Zealand White; PBNA, pseudovirion-based neutralization assay; VLP, virus-like particle.

Antisera of 10 NZW rabbits raised against RG1-VLP were analyzed for cross-neutralization of 20 mucosal HR HPV pseudovirions in duplicates using end point serial dilutions of 1:25--1:100,000. Neutralization titers were determined as described earlier ([@bib33]). Data previously published are indicated by "\*" ([@bib33]). Boxed titers indicate sera also tested for cross-neutralization *in vivo* ([Figure 2a--c](#fig2){ref-type="fig"}).

###### Cross-neutralization of mucosal LR and cutaneous HPV by RG1-VLP antisera *in vitro*

  **Pseudovirions**    **Neutralizing titer**   
  -------------------- ------------------------ -------
  *Low-risk mucosal*                            
   HPV6 \*             100                      50
   HPV11 \*            100                      \<25
   HPV32               50                       100
   HPV44               \<25                     \<25
  *Genus β*                                     
   HPV5 \*             100                      50
   HPV38               \<25                     \<25
  *Common cutaneous*                            
   HPV3                1,000                    1,000
   HPV4                \<25                     \<25
   HPV76               100                      100
  *Nonhuman*                                    
   BPV1                100                      100

Abbreviations: BPV1, bovine papillomavirus type 1; HPV, human papillomavirus; LR, low risk; VLP, virus-like particle.

Antisera of two rabbits (nos. 1 and 2) raised against RG1-VLP were tested for cross-neutralization of 4 LR mucosal, 2 genus β cutaneous, 3 common cutaneous HPVs, and nonhuman BPV1 as indicated. Neutralizing titers were determined as described in [Table 1](#tbl1){ref-type="table"}.
